Archives

Phil: $60 Million Growth Debt Raised For Advancing AI-Based Pharma Commercialization

By Amit Chowdhry ● Jul 15, 2025

Phil, a leading software-driven pharmaceutical commercialization platform, announced it has secured $60 million in growth debt financing from K2 HealthVentures.

Neuros Medical: $56 Million Series D Closed For Non-Opioid Pain Treatment

By Amit Chowdhry ● Jul 15, 2025

Neuros Medical, the maker of the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain, announced an oversubscribed $56 million Series D financing round. The funding, led by EQT Life Sciences with participation from existing investors, will support the U.S. commercialization and further development of its breakthrough non-opioid treatment.

Aria Systems: Interview With Co-Founder & Chief Innovation Officer Brendan O’Brien About The Cloud-Based Billing Platform

By Amit Chowdhry ● Jul 15, 2025

Aria Systems provides a cloud-based monetization platform that eliminates billing bottlenecks, enabling companies to launch and evolve their offerings quickly. Pulse 2.0 interviewed co-founder and Chief Innovation Officer Brendan O’Brien to learn more about the company.

ValidiFI: Interview With CEO John Gordon About The Fintech Company

By Amit Chowdhry ● Jul 14, 2025

ValidiFI is an analytics and technology company that connects bank account and payment insights to help companies in a variety of industries provide more confident, trustworthy, and transparent transactions. Pulse 2.0 interviewed ValidiFI CEO John Gordon to gain a deeper understanding of the company.

Audacious Inquiry: Interview With GM Greg Farnum About The Health Tech Company

By Amit Chowdhry ● Jul 14, 2025

Audacious Inquiry, now a PointClickCare company, brings on-the-ground expertise in health information systems, public health information systems, and health information exchange, combined with decades of experience working with and in federal and state agencies and health information exchanges.. Pulse 2.0 interviewed Audacious Inquiry General Manager Greg Farnum to gain a deeper understanding of the company.

Duranta: $7 Million Raised For Helping Landscapers Grow Their Businesses

By Amit Chowdhry ● Jul 14, 2025

Duranta, a company designed for landscapers and lawn care professionals, announced a $7 million seed funding round. The funding was led by several Silicon Valley firms, including Base10 Partners, Pear, Coalition Operators, and Sunshine Lake, with additional participation from angel investors such as GitHub CEO Thomas Dohmke and PagerDuty co-founder Andrew Miklas.

Illimis Therapeutics: $42 Million Series B Raised For Advancing CNS And Immune Disease Drug Development

By Amit Chowdhry ● Jul 14, 2025

Illimis Therapeutics announced it closed 58 billion KRW (approximately $42 million) in Series B funding. The round saw strong participation from both existing and new investors, signaling high confidence in the company's vision and technology.

Sphinx Acquiring Enigma For Enhancing Cybersecurity And Intelligence Solutions

By Amit Chowdhry ● Jul 14, 2025

Sphinx, a developer of Counterintelligence (CI) and cyber tools, announced it has acquired Enigma International. This acquisition significantly enhances Sphinx's ability to protect defense and commercial security clients from advanced threat actors by integrating Enigma's expertise in language and systems development.

Dreampath Diagnostics: Investment Raised From Summit Partners

By Amit Chowdhry ● Jul 14, 2025

Summit Partners has made a growth investment in Dreampath Diagnostics, a healthcare technology company that digitizes workflows in anatomical pathology laboratories.

Zimmer Biomet To Buy Monogram Technologies In $177 Million Deal

By Amit Chowdhry ● Jul 14, 2025

Zimmer Biomet (a global medical technology leader) has entered a definitive agreement to acquire Monogram Technologies (an orthopedic robotics company) for approximately $177 million in equity value. Monogram stockholders will also receive a non-tradeable contingent value right (CVR) potentially worth up to $12.37 per share based on future milestones. Both companies' boards have unanimously approved the transaction.